RightFit
RecruitingNot applicable

Confronting Cancer as a Community

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Procedures mentioned: Blood draws, Questionnaires

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "Patients undergo blood sample collection, collection of archival tumor tissue and genetic testing, and complete questionnaires on study."
  • "After return of genetic testing results, patients are followed up at 2 weeks, 6 months (one blood draw), 12 months, and then annually thereafter."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study looks at genes in blood and tumor tissue to better understand colon and rectal cancer in Hispanic adults. Genes carry traits passed down in families. Researchers hope to learn why treatments work differently for different people and how to better match treatments to each person.

This study aims to better understand the cause of colorectal cancer and how to find the best treatment for Hispanic patients with colorectal cancer. The genetic information in the blood and tissues may explain why patients who have the same type of cancer and receive the same treatment do not always have the same results. By combining genetic (certain qualities or traits passed from parents to offspring) information with clinical data, such as the responses of different kinds of cancers to different treatments, this study could lead to more knowledge about why certain cancers occur and why they respond differently to treatments. Information gathered from this study may help researchers match treatments to the genetics of each patient and the genetic changes in their tumor. This approach is known as personalized medicine.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You identify yourself as Hispanic.
  • You have had colon or rectal cancer at any time or stage, including if you are a cancer survivor.
  • You have a stored tumor tissue sample or plan to have one stored from a regular care procedure.
  • You are at least 18 years old.
  • You can understand the study and are willing to sign a form agreeing to join.
  • For the optional part studying the microbiome—the germs that live in your body—you must be under 40 or over 60. Any cancer stage is allowed.

Who can't join

  • You cannot understand the form agreeing to join the study. The listed rule about willingness to sign is unclear.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Self-reported Hispanic ethnicity * Diagnosed with colon or rectal cancer (at any time and stage; lifetime diagnosis and in survival are eligible) * Has a tumor tissue sample archived or plans to have tissue archived from a standard care procedure * Age \>= 18 years * Ability to understand and the willingness to sign a written informed consent. * For those who would like to participate in the optional microbiome characterization aspect of the study, the patient will have to be under 40 years old at any clinical cancer stage or over 60 years old at any clinical cancer stage. Exclusion Criteria: * Inability to understand and the willingness to sign a written informed consent

Study sites (2)

CA